Peter Greenleaf Sells 195,593 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. This trade represents a 9.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock traded up $0.10 during trading on Tuesday, reaching $8.08. The company had a trading volume of 3,640,172 shares, compared to its average volume of 1,449,999. The firm’s 50-day simple moving average is $8.13 and its 200 day simple moving average is $7.85. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The firm has a market capitalization of $1.16 billion, a PE ratio of -53.86 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $27,000. Tower Research Capital LLC TRC boosted its stake in Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $31,000. Finally, Natixis acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $49,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.